Drug repurposing in oncology: a systematic review of randomized controlled clinical trials

Ioakeim-Skoufa, Ignatios ; Tobajas-Ramos, Natalia ; Menditto, Enrica ; Aza-Pascual-Salcedo, Mercedes ; Gimeno-Miguel, Antonio ; Orlando, Valentina ; González-Rubio, Francisca ; Fanlo-Villacampa, Ana (Universidad de Zaragoza) ; Lasala-Aza, Carmen ; Ostasz, Ewelina ; Vicente-Romero, Jorge (Universidad de Zaragoza)

Resumen: Quality pharmacological treatment can improve survival in many types of cancer. Drug repurposing offers advantages in comparison with traditional drug development procedures, reducing time and risk. This systematic review identified the most recent randomized controlled clinical trials that focus on drug repurposing in oncology. We found that only a few clinical trials were placebo-controlled or standard-of-care-alone-controlled. Metformin has been studied for potential use in various types of cancer, including prostate, lung, and pancreatic cancer. Other studies assessed the possible use of the antiparasitic agent mebendazole in colorectal cancer and of propranolol in multiple myeloma or, when combined with etodolac, in breast cancer. We were able to identify trials that study the potential use of known antineoplastics in other non-oncological conditions, such as imatinib for severe coronavirus disease in 2019 or a study protocol aiming to assess the possible repurposing of leuprolide for Alzheimer’s disease. Major limitations of these clinical trials were the small sample size, the high clinical heterogeneity of the participants regarding the stage of the neoplastic disease, and the lack of accounting for multimorbidity and other baseline clinical characteristics. Drug repurposing possibilities in oncology must be carefully examined with well-designed trials, considering factors that could influence prognosis.

Idioma: Inglés

DOI: 10.3390/cancers15112972

Año: 2023

Publicado en: Cancers 15, 11 (2023), 2972
ISSN: 2072-6694

Factor impacto JCR: 4.5 (2023)

Categ. JCR: ONCOLOGY rank: 78 / 322 = 0.242 (2023) - Q1 - T1

Factor impacto SCIMAGO: 1.391 - Oncology (Q1) - Cancer Research (Q2)

Financiación: info:eu-repo/grantAgreement/ES/DGA-FEDER/B01-20R
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-RICAPPS/RD21-0016-0019

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Farmacología (Dpto. Farmac.Fisiol.y Med.L.F.)